1.04 USD
▲+0.01+0.97%
盘后 1.10 +5.77%
2026-11-20
市值
$6.30M
市盈率
—
EPS
-2.24
股息率
—
52 周区间
0.90 – 7.54
成交量
153.85K
Beta
-2.09
目标价
10.33
52W 低 0.9052W 高 7.54
价格走势
公司简介
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant e...